ESMO interim update on the use of targeted therapy in acute lymphoblastic leukaemia

ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia - European Society for Medical Oncology (ESMO)

- This ESMO Clinical Practice Guideline update provides key recommendations for managing acute lymphoblastic leukaemia.

- The update covers recent developments in the use of targeted therapies.

- Algorithms for the management of newly diagnosed and relapsed or refractory disease are provided.

- The author group encompasses a multidisciplinary group of experts from different institutions in Europe.

Recommendations are based on available scientific data and the authors’ collective expert opinion.


Read full Guideline